Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Reata Pharma
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Reata Pharma
< Previous
1
2
3
4
5
6
Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
December 09, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
December 09, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
December 08, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
December 08, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
December 08, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
December 07, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
December 07, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
December 06, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
November 18, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
November 08, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021
November 01, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
October 28, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces Presentations at the American Society of Nephrology Kidney Week 2021
October 15, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
September 30, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
August 09, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021
August 02, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.